Marinus Pharmaceuticals Inc logo

Marinus Pharmaceuticals Inc Share Price Today (NASDAQ: MRNS)

Marinus Pharmaceuticals Inc share price is $0 & ₹0.00 as on 9 Feb 2025 IST

▲

-0.55

(-100%)

Market is closed - opens 7 PM, 25 Jun 2025

Bell Icon

The stock has been delisted from the stock exchange on 10 Feb 2025

View live Marinus Pharmaceuticals Inc share price in Dollar and Rupees. Guide to invest in Marinus Pharmaceuticals Inc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Marinus Pharmaceuticals Inc, along with analyst recommendations, forecasts, and comprehensive financials.

Marinus Pharmaceuticals Inc (MRNS) Key Statistics

in dollars & INR

Previous Close
$0.55
Open
$0.5492
Market Capitalization
$30.3M
Today's Volume
$1.1M
Revenue TTM
$30.3M
EBITDA
$-128.7M
Earnings Per Share (EPS)
$-2.47
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-2986.55%

How to invest in Marinus Pharmaceuticals Inc Stock (MRNS) from India?

It is very easy for Indian residents to invest directly in Marinus Pharmaceuticals Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Marinus Pharmaceuticals Inc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Marinus Pharmaceuticals Inc or MRNS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Marinus Pharmaceuticals Inc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Marinus Pharmaceuticals Inc shares which would translate to null fractional shares of Marinus Pharmaceuticals Inc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Marinus Pharmaceuticals Inc, in just a few clicks!

Global Institutional Holdings in Marinus Pharmaceuticals Inc

  • Suvretta Capital Management, LLC

    9.19%

  • Franklin Resources Inc

    8.54%

  • TANG CAPITAL MANAGEMENT LLC

    8.51%

  • Sofinnova Ventures

    7.94%

  • Vanguard Group Inc

    5.08%

  • Bain Capital Life Sciences Investors, LLC

    4.88%

Analyst Recommendation on Marinus Pharmaceuticals Inc

Rating
Trend

Buy

    76%Buy

    23%Hold

    0%Sell

Based on 17 Wall street analysts offering stock ratings for Marinus Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)

About Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Organization
Marinus Pharmaceuticals Inc
Employees
165
CEO
Dr. Scott N. Braunstein M.D.
Industry
Health Technology

Management People of Marinus Pharmaceuticals Inc

NameTitle
Dr. Scott N. Braunstein M.D.
CEO, President & Chairman
Mr. Steven E. Pfanstiel C.M.A., M.B.A.
COO, CFO & Treasurer
Dr. Joseph Hulihan M.D.
Chief Medical Officer
Dr. Alex Aimetti Ph.D.
Chief Scientific Officer
Ms. Sonya Weigle
Senior VP of Investor Relations, Human Resources & Corporate Affairs
Ms. Martha E. Manning Esq., J. D.
Senior VP, General Counsel & Secretary
Molly Cameron
Director of Corporate Communications & Investor Relations
Dr. Kimberly A. McCormick Pharm.D.
Chief Regulatory & Quality Assurance Officer
Ms. Christina Shafer
Chief Commercial Officer
Mr. David Czekai
Chief Chemistry, Manufacturing & Controls Officer

Important FAQs about investing in MRNS Stock from India :

Can Indians buy Marinus Pharmaceuticals Inc shares?

Yes, Indians can invest in the Marinus Pharmaceuticals Inc (MRNS) from India.

With INDmoney, you can buy Marinus Pharmaceuticals Inc at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Marinus Pharmaceuticals Inc at zero transaction cost.

How can I buy Marinus Pharmaceuticals Inc shares from India?

It is very easy to buy Marinus Pharmaceuticals Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Marinus Pharmaceuticals Inc (MRNS) be purchased?

Yes, you can buy fractional shares of Marinus Pharmaceuticals Inc with INDmoney app.

What are the documents required to start investing in Marinus Pharmaceuticals Inc stocks?

To start investing in Marinus Pharmaceuticals Inc, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is today's market capitalisation of Marinus Pharmaceuticals Inc?

Today's market capitalisation of Marinus Pharmaceuticals Inc MRNS is 30.3M

Who is the Chief Executive Officer (CEO) of Marinus Pharmaceuticals Inc ?

Dr. Scott N. Braunstein M.D. is the current Chief Executive Officer (CEO) of Marinus Pharmaceuticals Inc.